Stocks:
5,169
ETFs:
2,288
Exchanges:
11
Market Cap:
$65.09T
24h Vol:
$8.59B
Dominance:
MSFT:4.90%
Stocklytics Platform

Performance History

Chart placeholder
Key Stats
Open$72.11
Prev. Close$72.51
EPS-6.45
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$3.57B
PE Ratio-
LOWHIGH
Day Range71.15
74.29
52 Week Range55.02
98.40
Ratios
P/B Ratio17.15
Revenue$270.60M
Operating M. %-91.58%
Earnings$0.00
Earnings Growth %-27.84%
EBITDA Margin %-90.37%
ROE %-231.68%
EPS-6.45

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

info
There's no data available for Analyst Forecast

Analyst Ratings

info
There's no data available for Analyst Ratings

Correlated Companies

PRICE$878.45
24H (%)arrow_drop_down0.55%
24H ($)-$4.88
MARKET CAP$771.28B
PRICE$497.12
24H (%)arrow_drop_down0.03%
24H ($)-$0.17
MARKET CAP$443.63B
PRICE$145.53
24H (%)arrow_drop_up0.06%
24H ($)$0.09
MARKET CAP$347.62B
PRICE$129.48
24H (%)arrow_drop_up0.08%
24H ($)$0.11
MARKET CAP$318.88B

About Axsome Therapeutics (AXSM)

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that is in Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial of for treating attention-deficit/hyperactivity disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Herriot Tabuteau M.D.
Headquarters
New York
Employees
393
Exchange
NASDAQ
add Axsome Therapeutics  to watchlist

Keep an eye on Axsome Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
What is Axsome Therapeutics 's (AXSM) price per share?

The current price per share for Axsome Therapeutics (AXSM) is $73.63. The stock has seen a price change of $1.12 recently, indicating a 1.54% change. This reflects the stock's recent market performance and investor sentiment.

help
What is the 52-week high and low for Axsome Therapeutics (AXSM)?

For Axsome Therapeutics (AXSM), the 52-week high is $98.4, which is 33.64% from the current price. The 52-week low is $55.02, the current price is 33.82% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help
Is Axsome Therapeutics (AXSM) a growth stock?

Axsome Therapeutics (AXSM) has shown an average price growth of 0.41% over the past three years. It has received a score of 86 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Axsome Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help
What is Axsome Therapeutics (AXSM) stock price performance year to date (YTD)?

As of the latest data, Axsome Therapeutics (AXSM) has a year-to-date price change of -4.45%. Over the past month, the stock has experienced a price change of -3.03%. Over the last three months, the change has been -2.53%. Over the past six months, the figure is 0.88%. Looking at a longer horizon, the five-year price change stands at 217.78%.

help
Is Axsome Therapeutics (AXSM) a profitable company?

Axsome Therapeutics (AXSM) has a net income of -$239.24M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 87.84% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -91.58% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $270.6M, although specific revenue growth data is currently not available. The gross profit is $237.7M. Operating income is noted at -$182.91M. Furthermore, the EBITDA is -$244.54M.

help
What is the market capitalization of Axsome Therapeutics (AXSM)?

Axsome Therapeutics (AXSM) has a market capitalization of $3.57B. The average daily trading volume is 935.48K, indicating the stock's liquidity and investor engagement.

News

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level

Stocklytics Platform

© 2024 Stocklytics, Inc. All rights reserved.

Stocklytics isn't a brokerage or dealer; it's supported by an affiliated investment adviser for an exchange traded fund. However, this adviser doesn't offer guidance to individual investors. None of the information on Stocklytics suggests buying or selling securities. The site and its newsletters aren't intended as investment advice. It's important to note that past performance isn't indicative of future results. Stocklytics doesn't guarantee the completeness or accuracy of its information. Also, the listed entities aren't affiliated with Stocklytics, LLC. Stock quotes come from InterActive Data, and Morningstar provides daily updated fundamental company data.

Stocklytics Discord public channelStocklytics X Social Media